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Abstract
Objective—Survival of patients with pancreatic adenocarcinoma is limited and few prognostic
factors are known. We conducted a two-stage genome-wide association study (GWAS) to identify
germline variants associated with survival in patients with pancreatic adenocarcinoma.
Design—We analyzed overall survival in relation to single nucleotide polymorphisms (SNPs)
among 1,005 patients from two large GWAS datasets, PanScan I and ChinaPC. Cox proportional
hazards regression was used in an additive genetic model with adjustment for age, sex, clinical
stage and the top four principal components of population stratification. The first stage included
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642 cases of European ancestry (PanScan), from which the top SNPs (P≤10−5) were advanced to a
joint analysis with 363 additional patients from China (ChinaPC).
Results—In the first stage of cases of European descent, the top-ranked loci were at
chromosomes 11p15.4, 18p11.21, and 1p36.13, tagged by rs12362504 (P=1.63×10−7), rs981621
(P=1.65×10−7), and rs16861827 (P=3.75×10−7), respectively. One-hundred thirty-one SNPs with
P ≤ 10−5 were advanced to a joint analysis with cases from the ChinaPC study. In the joint
analysis, the top-ranked SNP was rs10500715 (minor allele frequency, 0.37; P=1.72×10−7) on
chromosome 11p15.4, which is intronic to the SET binding factor 2 (SBF2) gene. The hazard ratio
(95% CI) for death was 0.74 (0.66–0.84) in PanScan I, 0.79 (0.65–0.97) in ChinaPC, and 0.76
(0.68–0.84) in the joint analysis.
Conclusion—Germline genetic variation in the SBF2 locus was associated with overall survival
in patients with pancreatic adenocarcinoma of European and Asian ancestry. This association
should be investigated in additional large patient cohorts.
Keywords
Pancreatic cancer; GWAS; single nucleotide polymorphism; SET binding factor 2
INTRODUCTION
Pancreatic cancer is a major cause of cancer-related death across the globe, and five-year
overall survival is approximately five percent.[1–2] Nevertheless, patient survival times are
variable and only partially explained by traditional clinical and pathologic features.[3]
Accumulating evidence indicates that germline genetic variability can provide important
prognostic information for patients with cancer.[4–6] One mechanism by which germline
genetic variability may impact patient survival is through modification of tumor-host
interactions. A defining feature of pancreatic adenocarcinoma is the recruitment of host
cells, including fibroblasts, immune cells, and endothelial cells, which surround the tumor in
a dense stromal matrix.[7–9] This host-derived desmoplastic stroma actively engages with
tumor cells and plays a critical role in promoting tumor development and progression.[10]
Notably, laboratory studies suggest that treatments which modify the interaction of
pancreatic cancer cells with its surrounding stroma can impact survival in genetically
engineered mouse models of pancreatic adenocarcinoma.[8, 11–12]
Prior studies of germline variants and pancreatic cancer survival have primarily focused on
the evaluation of candidate genes in pathways of suspected importance.[13–17] However,
this approach relies upon our relatively incomplete understanding of tumor and host biology.
In contrast, genome-wide approaches are available that allow a more comprehensive
evaluation of germline genetic variants that is not reliant upon a priori hypotheses. Recently,
genome-wide association studies (GWAS) have identified several genetic variants
associated with the development of pancreatic adenocarcinoma in European and Chinese
populations.[18–20] In a two-stage genome-wide study of survival, we used these data to




The Pancreatic Cancer Cohort Consortium (PanScan) genome wide association study
(GWAS) has been described previously, in detail.[18, 21] In short, PanScan I included cases
and controls from 11 prospective cohort studies from European populations in the United
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States and Europe, including Alpha-Tocopherol Beta-Carotene Cancer Prevention Study
(ATBC), CLUE II, American Cancer Society Cancer Prevention Study-II (CPS II);
European Prospective Investigation into Cancer and Nutrition Study (EPIC); Health
Professional's Follow-up Study (HPFS); New York University Women's Health Study
(NYU-WHS); Nurses' Health Study (NHS); Physicians' Health Study I (PHS I); Prostate,
Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO); Women’s Health Initiative
(WHI); and Women’s Health Study (WHS). In each cohort, a defined population of subjects
was followed prospectively with assessments of lifestyle factors and ascertainment of cancer
diagnoses. Cases included subjects with incident primary pancreatic adenocarcinoma (ICD-
O-3 code C250-C259 or C25.0-C25.3, C25.7-C25.9). All subjects with non-exocrine
pancreatic tumors (C25.4, histology type, 8150, 8151, 8153, 8155, 8240, 8246) were
excluded.
Each cohort study selected participants with blood or buccal cells collected prior to cancer
diagnosis. Incident pancreatic cancer cases identified by self-report, report of next-of-kin,
linkage with local or national cancer registries, or through national death indices were
confirmed by subsequent medical record review, cancer registry report, and/or death registry
report, without prior knowledge of genetic data. In the 11 participating cohorts, covariate
data were collected though written questionnaires or in-person interviews. Data were
requested from each cohort on participants’ age, gender, and race/ethnicity (European,
Asian, African, other). Detailed descriptions of data collection methods have been published
previously.[18, 21] Cohorts obtained consent from participants and approval from their
Institutional Review Board (IRB). The Special Studies Institutional Review Board (SSIRB)
of the National Cancer Institute approved the pooled PanScan study.
For the current survival analysis, each cohort also provided survival time and stage
information for pancreatic cancer cases included in PanScan. Survival time was defined as
the number of days between the date of diagnosis and the date of death or date of last known
contact. Stage data were harmonized into three categories: (1) local disease amenable to
surgical resection; (2) locally advanced disease with extra-pancreatic extension rendering it
unresectable, but without distant metastases, (3) distant metastatic disease. For eight cohorts
(CLUE II, EPIC, HPFS, NHS, NYU-WHS, PHS, PLCO and WHS), American Joint
Committee on Cancer (AJCC)/International Union for Cancer Control (IUCC) TNM staging
[22] was converted to the above categories, with AJCC/IUCC stages I and II indicating local
disease, stage III indicating locally advanced disease, and stage IV indicating metastatic
disease. Two cohorts (CPS and WHI) provided data using Surveillance Epidemiology End
Results summary staging,[23] which classifies tumors as localized, regional, or distant.
These stages were included as local, locally advanced and metastatic disease, respectively.
Stage data were not available for one study (ATBC). Given the known strong association
between stage and survival, subjects of European descent were included in the final analysis
if they had available survival time and stage information, in addition to genotype data. From
PanScan I, 1323 cases of European descent were available with genome-wide genotype data
and survival time. Among these cases, 642 cases had stage information and were included in
the analysis (Figure 1 and Supplementary Table 1). Median survival times were slightly
shorter among the full population of patients with survival information versus the subset of
patients with stage information (Supplemental Table 1). Overall, median survival time
(MST) was 5.0 months for all cases and 5.9 months for the subset of cases with available
stage data. Age and gender were similar in the full PanScan population of European descent
(median age, 68 years; 48% male) and the population with survival and stage information
(median age, 71 years; 37% male).
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The ChinaPC case-control GWAS has been described previously in detail.[20] In short, a
GWAS was performed among pancreatic cancer cases and controls collected in an ongoing
molecular epidemiological study of pancreatic cancer. These case subjects were recruited
from Cancer Hospital, Chinese Academy of Medical Sciences (Beijing), and Cancer
Hospital, Fudan University (Shanghai), between 2000 and 2011. At recruitment, informed
consent was obtained from each subject. The study was approved by the Institutional
Review Board of the Chinese Academy of Medical Sciences Cancer Institute. All case
subjects had pancreatic ductal adenocarcinoma confirmed histopathologically or
cytologically by at least two pathologists according to the World Health Organization
classification. Genomic DNA for GWAS analysis was isolated from peripheral blood
lymphocytes at the time of diagnosis. Characteristics and clinical information including age,
sex, race and tumor stage, were obtained from patients’ medical records. As for the PanScan
subjects, survival time was defined as the number of days between the date of diagnosis and
the date of death or date of last known contact. Stage data were harmonized into three
categories: (1) local disease amenable to surgical resection; (2) locally advanced disease
with extra-pancreatic extension rendering it unresectable, but without distant metastases, (3)
distant metastatic disease. Those subjects with available genome-wide genotype data,
survival time, and stage information were included in the analysis. From ChinaPC, 600
cases had genome-wide genotype data and survival times. After exclusion of 237 cases
without stage information, 363 cases were available for analysis. Median survival times
were 7.1 months in both those cases with available stage information and those cases
without such information.
Genotype and Imputation Analysis
Genotypes of patients in PanScan and ChinaPC were generated using the HumanHap550
chip (Illumina, San Diego, CA) and Affymetrix GeneChip Human Mapping 6.0 set
(Affymetrix, Santa Clara, CA), respectively. The procedures of genotyping and quality
control in each genome-wide association study have been described previously. [18, 20] In
brief, samples with <98% completion and SNP assays with call rates <90% were excluded.
Only SNPs with minor allele frequency >0.01 and mapped on autosomal chromosomes were
included for analysis. A principal component analysis (PCA) of DNA samples in this study
was performed with EIGENSTRAT. Four principal components were effective for
distinguishing significant population groups and were included as quantitative covariates to
correct for genetic admixture. To increase the spectrum of variants tested in the current
study of overall survival, we used MACH software to impute untyped markers using linkage
disequilibrium (LD) and haplotype information from HapMap phase II CEU and CHB+JPT
as the reference sets for PanScan and ChinaPC participants, respectively. After quality
control of imputation data, 2,731,086 SNPs in PanScan and 2,307,550 SNPs in ChinaPC
were available for analysis.
Cis-eQTL analysis
To examine gene expression differences by genotype at our top locus, we inspected a
publically available eQTL database.[24] The database includes 405 children of British
descent, organized into 206 sibships, including 297 sib pairs and 11 half-sib pairs. Global
gene expression in lymphoblastoid cell lines was measured using Affymetrix HG-U133 Plus
2.0 chips. All 405 children and their parents were genotyped using the Illumina Sentrix
Human-1 Genotyping BeadChip. The number of principal components used was chosen to
maximize the number of cis-eQTLs with genome-wide significance. Association analysis
was applied with the FASTASSOC option implemented in MERLIN.
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For each of the selected SNPs, we performed Cox proportional hazards regression under a
log-additive genetic model with adjustment for covariates that might influence patient
survival, including age (continuous), sex (male or female), stage of disease (local, locally
advanced and metastatic as ordinal categories) and the top four principal components of
population stratification in both PanScan I and ChinaPC studies.[18, 20] The overall
survival time was defined as the time from pancreatic cancer diagnosis to either death or the
last known date alive. Patients known to be alive were censored at the time of last contact.
The top SNPs with P≤10−5 found in PanScan were advanced to a combined analysis in
patients independently recruited from the ChinaPC study. To summarize results for the two
datasets, we performed a meta-analysis to obtain the summary HR and 95% CI using
METAL software (http://www.sph.umich.edu/csg/abecasis/metal). Haploview software was
used to determine pair-wise linkage disequilibrium structure across the studied genomic
regions. Kaplan-Meier survival estimates were plotted and P-values were assessed using the




The characteristics of the 642 pancreatic cancer cases from the PanScan cohort and the 363
cases from the ChinaPC study are shown in Table 1. Median follow-up time for cases still
alive was 64 months in PanScan and 17 months in ChinaPC. In PanScan, 609 (94.9%)
patients had died, while 334 (92.0%) had died in the ChinaPC study. In the combined
analysis, we included 1,005 patients with pancreatic cancer, 19.6% with localized disease,
32.5% with locally advanced disease, and 47.9% with metastatic disease. As expected, stage
was strongly associated with survival in both studies (P<0.0001); median survival time
(MST) was 13.5, 9.7 and 3.8 months for patients with local, locally advanced and metastatic
disease, respectively, in the combined study. The MST for patients in PanScan and ChinaPC
studies were 5.9 months and 7.1 months, respectively.
Germline Variants Associated with Incident Pancreatic Cancer or Patient Survival in
Previous GWAS
Four susceptibility loci, 13q22.1, 1q32.1, 5p15.33 and 9q34, have been associated with
pancreatic cancer risk in two pancreatic cancer GWAS of European ancestry (PanScan I and
II).[18–19] To determine if the top SNPs at these loci might also be associated with patient
survival, we investigated the associations between these SNPs and survival time in the
PanScan cohort. We also evaluated rs167020 on chromosome 7q36, which was associated
with incident pancreatic cancer in the prospective cohorts participating in PanScan I.[18]
None of the top SNPs at these loci were significantly associated with survival (P>0.05)
(Table 2).
We then investigated a genetic locus on chromosome 6, which was associated with survival
in patients with advanced pancreatic adenocarcinoma participating in a randomized clinical
trial of gemcitabine plus placebo versus gemcitabine plus bevacizumab (CALGB 80303).
[25] The top SNP from the analysis in CALGB 80303 (rs763780) was also associated with
survival time in the PanScan cohort (P = 0.0008). However, the risk allele identified in
CALGB 80303 was protective in the PanScan cohort. Comparing the survival time of
patients with the TC genotype versus the TT genotype (referent) resulted in a HR of 3.3
(95% CI, 2.1–5.1) in CALGB 80303,[26] while it resulted in a HR of 0.64 (95% CI, 0.50–
0.83) in PanScan. We noted similar results when including only subjects with metastatic
disease in the PanScan cohort (data not shown). In CALGB 80303, results were similar after
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stratification by treatment arm.[25] Although further investigation is required, differences in
patient populations between a large, randomized phase III trial and participants from
pospective cohorts may have contributed to the discordant results.
Genetic Variants Associated with Patient Survival in Genome-wide Genotyping
The manhattan plot for the GWAS of pancreatic cancer survival in PanScan is shown in
Supplementary Figure 1. We identified three independent regions most associated with
survival on chromosomes 11p15.4 (four SNPs), 18p11.21 (12 SNPs) and 1p36.13 (one
SNP) , which were tagged by rs12362504 (HR, 1.40; 95% CI, 1.23–1.58; P=1.63×10−7),
rs981621 (HR, 1.39; 95% CI, 1.23–1.57; P=1.65×10−7) and rs16861827 (HR, 1.70; 95% CI,
1.39–2.09; P=3.75×10−7), respectively (Table 3 and Supplemental Table 2). These SNPs
were clustered in SBF2 on Chr11p15.4, C18orf1 on Chr18p11.21, and IGSF21 on
Chr1p36.13. LD plots of the SNPs on chromosomes 11p15.4 and 18p11.21 are shown in
Supplementary Figure 2. In 200 kb regions flanking rs16861827, there were 56 nominally
significant SNPs with P-values ranging from 4.96×10−5 to 0.048.
We selected the SNPs with P ≤ 10−5 from PanScan (131 SNPs) to evaluate in a joint
analysis with cases from the ChinaPC study (Supplementary Table 2). In the joint analysis,
the top two SNPs, rs10500715 and rs7106914, were identified on chromosome 11p15.4.
These two SNPs were also located in the SBF2 gene, 43,520 and 48,429 base pairs from the
top SNP identified in the PanScan analysis, respectively. These two SNPs were in perfect
LD with each other in both populations; we selected rs10500715 as the tag SNP in this
region for further analysis. In PanScan and ChinaPC participants, rs10500715 was
associated with a HR for death in an additive model of 0.74 (95% CI, 0.66–0.84) and 0.79
(95% CI, 0.65–0.97), respectively. In the meta-analysis of the two studies, we observed a
HR of 0.76 (95% CI, 0.68–0.84) with a P-value of 1.72×10−7 (Table 4). The P-value for
heterogeneity was 0.30 across the two studies. The association of rs10500715 with patient
survival was similar by disease stage, with a HR of 0.80 (95% CI, 0.64–1.01) in patients
with localized disease, HR of 0.78 (95% CI, 0.65–0.93) in those with locally advanced
disease, and HR of 0.81 (95% CI, 0.70–0.92) in those with metastatic disease. rs10500715
genotype was not statistically significantly associated with clinical stage in a joint analysis
(P=0.10).
In a dominant model for rs10500715, the median overall survival was 4.1 months for cases
with the TT genotype and 7.0 months for those with TG or GG genotype in PanScan (Figure
2). Multiple additional SNPs at the SBF2 gene locus were of marginal statistical significance
in the PanScan cohort and combined analysis (Figure 3); seven SNPs in high LD (r2=0.76–
1.00) in PanScan were associated with overall survival with P-values of 8.64×10−7 to
0.0002. We examined whether the top SNPs in SBF2 map to reported expression
quantitative trait loci (eQTLs) for nearby genes using data from a published eQTL dataset.
[24] However, we did not find that the SNPs were associated with known eQTLs in this
dataset.
DISCUSSION
In this genome-wide interrogation of germline genetic variants associated with pancreatic
cancer survival, we used a two-stage analytical approach that took advantage of two large
GWAS of pancreatic cancer in two independent populations. In both the PanScan population
that included cases of European descent and in a combined analysis with cases from China,
SNPs in the SET binding factor 2 (SBF2) gene were associated with survival time among
patients with pancreatic adenocarcinoma. With a P-value <5×10−7, this association is likely
to be replicated in follow-up studies,[26] although it did not reach P<5×10−8, which is often
cited as a threshold for genome-wide significance in GWAS of incident disease. We also
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identified two additional genetic loci associated with pancreatic cancer survival in the
PanScan cohort, which were not significant at P<5×10−7 in the combined analysis. Several
loci associated with incident pancreatic cancer in two prior PanScan studies were not
associated with patient survival.
The SNPs most highly associated with pancreatic cancer survival in the PanScan population
(rs12362504) and in the joint analysis (rs10500715) are located intronic to the SBF2 gene
and are in moderate linkage disequlibrium (r2=0.33) in the CEU population. SBF2 spans >
500 kb and 40 exons on chromosome 11p15.4 and is highly conserved across eukaryotes.
[27, 28] This gene encodes for a protein in the myotubularin family of lipid phosphatases
and is also known as myotubularin-related protein-13 (MTMR13). Similar to the known
tumor suppressor gene phosphatase and tensin homolog (PTEN),[29] MTMR proteins
function as phosphoinositide- 3-phosphatases and antagonize the activity of specific classes
of phosphatidylinositol 3-kinases.[30] Although it contains an inactive phosphatase domain,
SBF2 enhances the catalytic activity of and may alter the cellular localization of MTMR2, a
phosphatase-competent member of the MTMR family.[31]
Notably, mutations in either SBF2 or MTMR2 lead to the development of Charcot-Marie-
Tooth disease type 4B (CMT4B), an autosomal recessive disorder characterized by severe
demyelinating peripheral neuropathy.[32–33] The known mutations in human SBF2 lead to
a shortened or truncated protein,[33–34] and mice genetically engineered for loss of murine
SBF2 develop peripheral neuropathy similar to that seen in humans with CMT4B.[35–36]
The pathogenic mechanisms appear related to altered membrane trafficking of 3-
phosphoinositides within nerve-supporting Schwann cells, due to malfunctioning of the
SBF2-MTMR2 complex.[37] Importantly, in other cell types, SBF2 and MTMR2 appear to
influence the sorting and degradation of cell surface receptors, such as the epidermal growth
factor receptor (EGFR), with resultant alterations in downstream signaling.[30] For the
SNPs identified in SBF2 in the current study, we did not identify alterations in expression of
SBF2 or nearby genes using a publically available eQTL database. Further investigation will
be necessary to determine the causative one or more SNPs marked by the single nucleotide
changes identified in the current study, and the functional impact of such changes.
Recently, two genome wide association studies have implicated SBF2 as a susceptibility
locus for circulating lipoproteins in European populations[28] and human stature in
European and Chinese populations.[38] The most strongly associated SNPs from these
studies were rs7938647 with circulating HDL and rs10734652 with stature, also located
within introns of SBF2. The most strongly associated SNP in our combined analysis,
rs10500715, is in moderate linkage disequilibrium with rs7938647 and rs10734652, with r2
values of 0.40 and 0.56, respectively in the PanScan cohort. Interestingly, pancreatic cancer
incidence or mortality has been associated with height, obesity and metabolic derangements
related to insulin resistance.[39–42]
In the PanScan population, variants at chromosomes 18p11.21 and 1p36.13 were also
associated with survival. However, these associations were no longer significant in the
combined analysis with cases from the ChinaPC study. Furthermore, the genes at these loci,
chromosome 18 open reading frame 1 (C18orf1) and immunoglobin superfamily member 21
(IGSF21), respectively, encode for proteins with unclear function. Additional studies of
these variants in populations of European and Asian ancestry will be necessary to determine
whether these loci are truly associated with survival of patients with pancreatic
adenocarcinoma.
The current study has a number of important strengths. In the PanScan population, large
numbers of cohort participants provided germline DNA at a baseline time point and were
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then followed prospectively for development of disease. Pancreatic cancer diagnoses were
subsequently determined from notification near the time of diagnosis or review of cancer
and death registries. Therefore, the full spectrum of cases were ascertained, in terms of
disease aggressiveness and stage of disease, rather than only those patients well enough to
be captured in case-controls studies. This is of particular importance to studies of rapidly
fatal diseases, such as pancreatic cancer, in which a better-prognosis population can result
when subjects donate biologic samples after diagnosis. Furthermore, our study included a
large number of pancreatic cancer cases with genome-wide SNP data, and these data
originated from two well-established GWAS with strict quality control procedures.[18–20]
We also pursued a two-stage design, with an initial analysis in PanScan participants and a
subsequent combined analysis with ChinaPC participants, in an attempt to reduce the
likelihood of false positive results.
Our study also has limitations. Among our participants, treatment programs likely varied,
and we could not control for differences in treatment as the PanScan cohorts generally did
not collect this information. Nevertheless, chemotherapy and radiation have had only a
modest impact on patient survival,[3] and it is highly unlikely that treatment programs
varied systematically by germline genotype. As described, we also performed combined
analyses with a second group of pancreatic cancer cases, drawn from a case-control study in
China, to reduce the chance of false positive results. However, linkage disequilibrium differs
between Europeans and Asians, which can lead to false negative results in analyses that
combine subjects of different race/ethnicity. Specifically, some loci may impact survival
only in a particular race/ethnicity or the index signal may be best tagged by different
polymorphisms in subjects of different race/ethnicity; phenomena demonstrated in studies of
cancer risk.[19–20, 43–44] The difference in study design (nested prospective cohort study
versus hospital-based case-control study) can also lead to false negative results in combined
analyses due to recruitment of patients with dissimilar disease characteristics. However, all
patients were known to have pancreatic adenocarcinoma, and all had available information
on disease stage. Our top SNPs had significance levels of P<5×10−7; further studies are
necessary to replicate these findings in additional large patient cohorts. As is inherent in the
GWAS design, we have identified loci associated with pancreatic cancer survival, but
further work is necessary to investigate the biologic mechanisms by which polymorphisms
at these loci impact survival. Although we examined published eQTL datasets, we did not
identify known gene expression changes related to the most significant SNPs in SBF2.
Finally, we utilized overall mortality data in our analyses, as opposed to pancreatic cancer-
specific mortality. However, pancreatic cancer is a highly lethal malignancy with cure rate
less than five percent, such that overall mortality is a good surrogate for cancer-specific
mortality in patients with this disease.
In summary, we performed a genome-wide analysis of germline genetic variants and
survival of patients with pancreatic adenocarcinoma. Our large study implicates the SBF2
locus on chromosome 11p15.4 as a genetic region associated with overall survival among
these patients. These results further implicate altered membrane trafficking of 3-
phosphoinositides in pancreatic cancer growth and progression. Additional large datasets are
needed to evaluate germline genetic variants and survival in patients with this highly lethal
malignancy.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Significance of this study
What is already known about the subject?
► Five-year overall survival of patients with pancreatic cancer is approximately
five percent.
► Germline genetic variability can provide important prognostic information
for patients with cancer.
► Genome-wide association studies (GWAS) have identified several genetic
variants associated with the development of pancreatic adenocarcinoma in
European and Chinese populations, but few studies have examined variants
related to survival
What are the new findings?
► Previously identified genetic loci associated with the development of
pancreatic adenocarcinoma were not associated with survival among those
with the disease
► In the first stage of the GWAS of patient survival, three regions, 11p15.4,
18p11.21, and 1p36.13, were the top-ranked loci among patients of European
ancestry
► In the joint analysis of > 1000 pancreatic cancer cases, variants at the SBF2
gene on chromosome 11p15.4 defined the top genetic locus associated with
overall survival among patients of European and Chinese descent.
► rs10500715 in SBF2 was associated with a HR for death in an additive model
of 0.76 (95% CI, 0.68–0.84; P-value, 1.72×10−7) which was similar in
European and Chinese populations and by disease stage.
How might it impact on clinical practice in the foreseeable future?
► In patients with pancreatic adenocarcinoma, several germline variants were
associated with overall survival. If confirmed in further replication and
functional studies, these variants may add important information to define
patient prognosis, with the potential to impact treatment decisions and
clinical trial design.
► Our results highlight a potential role for SBF2 in pancreatic tumorigenesis
and further implicate altered membrane trafficking of 3-phosphoinositides in
pancreatic cancer growth and progression.
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Flow chart of PanScan case eligibility
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Kaplan-Meier curves by rs10500715 T>G genotypes using a dominant model in the
PanScan and Combined Analyses
Abbreviations: CI, confidence interval; HR, hazard ratio
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Association with survival and linkage disequilibrium of single nucleotide polymorphisms at
the SBF2 gene locus
Association results are shown in the top panel for the joint analysis (green triangles),
PanScan I (blue squares) and ChinaPC (red circle). The linkage disequilibrium plot was
based on genotypes in the PanScan I cohort. Locations are from NCBI Genome Build 36.
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Table 2
Hazard ratios and median survival times by genetic variants previously associated with incident pancreatic
cancer in PanScan
SNP, Chromosome, Gene No. (%) MST* HR (95% CI)† P†
rs9543325, Chr13, None 1.09 (0.96–1.24) 0.1769
TT 207 (32.2) 6.1
TC 331 (51.6) 6.4
CC 104 (16.2) 5.1
rs3790844, Chr1, NR5A2 1.04 (0.90–1.21) 0.5699
AA 414 (64.5) 5.4
AG 203 (31.6) 6.6
GG 25 (3.9) 6.9
rs401681, Chr5, CLPTM1L-TERT 1.06 (0.95–1.19) 0.2916
CC 189 (29.4) 6.5
CT 316 (49.2) 5.2
TT 137 (21.4) 7.7
rs505922, Chr9, ABO 1.05 (0.93–1.18) 0.4590
TT 224 (34.9) 5.1
TC 312 (48.6) 5.3
CC 106 (16.5) 8.0
rs167020, Chr7, SHH 0.99 (0.87–1.12) 0.8724
GG 314 (48.9) 5.7
GA 264 (41.1) 6.1
AA 64 (10.0) 5.0
*
MST = median survival time, months
†
HR (95% CI) = hazard ratio (95% confidence interval). HR and P-value calculated using multivariable-adjusted Cox regression under a log-
additive genetic model, adjusting for age, sex, stage of disease, and the top four principal components of population stratification
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Table 3
Hazard ratios and median survival times by genotype for significant tagSNPs (P<5×10−7) in PanScan survival
GWAS.
SNP, Chromosome, Gene No. (%) MST* HR (95% CI)† P†
rs12362504, Chr11p15.4, SBF2 1.40 (1.23–1.58) 1.63×10−7
TT 319 (49.7) 6.9
TC 266 (41.4) 4.6
CC 57 (8.9) 5.1
rs981621, Chr18p11.21, C18orf1 1.39 (1.23–1.57) 1.65×10−7
AA 266 (41.4) 8.1
AG 298 (46.4) 5.0
GG 78 (12.2) 3.7
rs16861827, Chr1p36.13, IGSF21 1.70 (1.39–2.09) 3.75×10−7
CC 513 (79.9) 6.5
CT 125 (19.5) 3.8
TT 4 (0.6) 2.5
*
MST = median survival time, months
†
HR (95% CI) = hazard ratio (95% confidence interval). HR and P-value calculated using multivariable-adjusted Cox regression under a log-
additive genetic model, adjusting for age, sex, stage of disease, and the top four principal components of population stratification
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Table 4
Hazard ratios and median survival times by rs10500715 T>G genotypes in the PanScan and ChinaPC studies
rs10500715
No. (%) MST* HR (95% CI)† P†
PanScan Study 0.74 (0.66–0.84) 2.33×10−6
TT 204 (31.8) 4.1
GT 313 (48.8) 6.6
GG 125 (19.4) 7.5
ChinaPC Study 0.79 (0.65–0.97) 0.0216
TT 235 (64.7) 6.1
GT 113 (31.1) 7.9
GG 15 (4.2) 5.4
Meta-Analysis 0.76 (0.68–0.84) 1.72×10−7
TT 439 (43.7) 5.7
GT 426 (42.4) 7.1
GG 140 (13.9) 7.3
*
MST = median survival time, months
†
HR (95% CI) = hazard ratio (95% confidence interval). HR and P-value calculated using multivariable-adjusted Cox regression under a log-
additive genetic model, adjusting for age, sex, stage of disease, and the top four principal components of population stratification
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